Business Context and Reporting Period
Company: Alphatec Holdings, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2008
Business Overview: Alphatec is a medical technology company focused on the design, development, manufacturing, and marketing of products for the surgical treatment of spine disorders, with a specific emphasis on the "aging spine" market. The company operates primarily in the U.S., Japan, and Europe, utilizing a network of independent distributors and direct sales representatives. It maintains in-house manufacturing capabilities for most of its implants.
Key Financial Metrics (Year Ended Dec 31, 2008)
| Metric | 2008 Value | 2007 Value |
|---|---|---|
| Revenues | $101.3 million | $80.0 million |
| Gross Profit | $64.7 million (63.9% margin) | $50.2 million (62.7% margin) |
| Operating Loss | $(27.8) million | $(19.7) million |
| Net Loss | $(29.3) million | $(20.2) million |
| Cash and Cash Equivalents | $18.3 million | $25.8 million |
| Working Capital | $34.3 million | $39.8 million |
| Total Debt (Long-term + Current) | $28.6 million | $4.2 million |
Note: The increase in debt is primarily due to a new $30 million credit facility entered into in December 2008 to replace prior financing.
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 26.6% to $101.3 million, driven by a $14.7 million increase in U.S. sales (Zodiac, Novel, Trestle, Solanas lines) and a $4.4 million increase in Asia. The company also recognized $2.1 million in initial European sales in Q4 2008.
- Operating Expenses: Total operating expenses rose to $92.5 million from $69.9 million. This includes a one-time $11.0 million litigation settlement with Biedermann and DePuy regarding patent infringement. Excluding this settlement, operating expenses increased due to higher R&D ($13.0M vs $6.4M) and Sales & Marketing ($42.4M vs $33.5M) costs.
- Profitability: While gross margin improved slightly to 63.9%, the company reported a net loss of $29.3 million, compared to $20.2 million in 2007. The loss per share was $0.63 (basic and diluted).
- Debt Structure: The company refinanced its debt in December 2008, securing a $15 million term loan and a $15 million working capital line of credit from Silicon Valley Bank and Oxford Finance Corporation. This replaced a previous line of credit with GECC.
Guidance, Outlook, Risks, and Unusual Items
- Outlook: Management believes current cash ($18.3 million) and available credit ($3.5 million) are sufficient to fund operations through at least December 31, 2009. The company expects to need to invest in working capital and surgical instruments to support revenue projections.
- Unusual Items:
- Litigation Settlement: A $11.0 million one-time charge was recorded in 2008 to settle patent litigation with Biedermann and DePuy.
- IPR&D Charges: The company recorded $2.8 million in in-process research and development expenses, primarily for licensing new technologies (OsseoFix, Expandable VBR, OsseoScrew).
- Key Risks:
- Credit Facility Covenants: The new credit facility requires the company to meet minimum quarterly revenue and Adjusted EBITDA covenants. Failure to meet these could result in a default and acceleration of debt.
- Litigation: The company is defending a lawsuit filed by four surgeons claiming royalties on polyaxial screw sales. A judgment in excess of $100,000 could trigger a default under the credit facility.
- Supply Chain: The company relies on a single supplier (Invibio) for PEEK material and limited sources for allograft (human tissue).
- Reimbursement: Sales depend on third-party payor reimbursement, which faces pressure from cost-containment measures.
Investor Verification Checklist
- Covenant Compliance: Verify if the company met the escalating quarterly revenue and Adjusted EBITDA covenants for the new credit facility in 2009.
- Litigation Status: Monitor the outcome of the lawsuit filed by the "claimant surgeons" regarding polyaxial screw royalties, as an adverse judgment could trigger debt acceleration.
- European Expansion: Assess the sustainability of the new European revenue stream, noting that revenue recognition was deferred for some distributors due to extended payment terms.
- Inventory Levels: Review inventory reserves for excess and obsolete items, which increased to $11.2 million, given the company's strategy of rapid product innovation.
- Product Pipeline: Track the regulatory progress (FDA 510(k) or PMA) for key pipeline products like OsseoFix and OsseoScrew, which require clinical data.